Evaluation on the Cost-effectiveness of Four New Antidepressants
Author(s): CHEN Ce, HUANG Zi-ye, CHEN Guang-dong, CHEN Ji-na, TU Wen-zhen, SHAN Jian-min, YE Jia-en
Pages: 39-41
Year: 2014 Issue: 10
Journal: Hospital Management Forum
Keyword: Antidepressant; Depression; Cost-effectiveness analysis;
Abstract: Objective To evaluate the cost-effectiveness of 4 new antidepressants for treatment of depression. Method 104 patients, who met the criteria of first-onset of depressive disorder, were randomly assigned into 4 groups and treated with duloxetine capsules, venlafaxine sustained-release capsules, mirtazapine tablets, escitalopram tablets respectively for 6 weeks. The Hamilton Depressive Scale (HAMD17) was adopted to assess efficacy and cost-effectiveness analysis was also applied. Results The efficient rate of four groups was 73.08%, 69.23%, 69.23%and 73.08%(P>0.05) respectively, and the costs were 768.6 Yuan, 562.8 Yuan, 751.2 Yuan and 751.8 Yuan. The cost-effectiveness ratio for healing was 13.32, 11.26, 12.36, and 13.97 and for efficacy was 10.51, 8.13, 8.25, and 10.28. Conclusion The regimen of venlafaxine sustained-release capsule is superior in terms of the cost-effectiveness ratios.
Pages: 39-41
Year: 2014 Issue: 10
Journal: Hospital Management Forum
Keyword: Antidepressant; Depression; Cost-effectiveness analysis;
Abstract: Objective To evaluate the cost-effectiveness of 4 new antidepressants for treatment of depression. Method 104 patients, who met the criteria of first-onset of depressive disorder, were randomly assigned into 4 groups and treated with duloxetine capsules, venlafaxine sustained-release capsules, mirtazapine tablets, escitalopram tablets respectively for 6 weeks. The Hamilton Depressive Scale (HAMD17) was adopted to assess efficacy and cost-effectiveness analysis was also applied. Results The efficient rate of four groups was 73.08%, 69.23%, 69.23%and 73.08%(P>0.05) respectively, and the costs were 768.6 Yuan, 562.8 Yuan, 751.2 Yuan and 751.8 Yuan. The cost-effectiveness ratio for healing was 13.32, 11.26, 12.36, and 13.97 and for efficacy was 10.51, 8.13, 8.25, and 10.28. Conclusion The regimen of venlafaxine sustained-release capsule is superior in terms of the cost-effectiveness ratios.
Related Articles